1. Academic Validation
  2. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

  • J Med Chem. 2004 Dec 30;47(27):6658-61. doi: 10.1021/jm049486a.
Louis J Lombardo 1 Francis Y Lee Ping Chen Derek Norris Joel C Barrish Kamelia Behnia Stephen Castaneda Lyndon A M Cornelius Jagabandhu Das Arthur M Doweyko Craig Fairchild John T Hunt Ivan Inigo Kathy Johnston Amrita Kamath David Kan Herbert Klei Punit Marathe Suhong Pang Russell Peterson Sidney Pitt Gary L Schieven Robert J Schmidt John Tokarski Mei-Li Wen John Wityak Robert M Borzilleri
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA. louis.lombardo@bms.com
Abstract

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

Figures
Products